{"id":40196,"date":"1999-09-01T12:05:00","date_gmt":"1999-09-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie"},"modified":"1999-09-01T12:05:00","modified_gmt":"1999-09-01T10:05:00","slug":"aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/","title":{"rendered":"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie)"},"content":{"rendered":"<p>In nur wenigen L\u00e4ndern der Welt wird die perkutane Angioplastie der Koronararterien (PTCA) so h\u00e4ufig eingesetzt wie in Deutschland. Trotz sinkender Pr\u00e4valenz von instabiler Angina pectoris und Myokardinfarkt steigt die Zahl der Katheterinterventionen steil an. Die Indikation zur PTCA wird also kontinuierlich ausgeweitet. Dabei ist ein im Vergleich zur medikament\u00f6sen Therapie g\u00fcnstigerer Effekt der PTCA [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In nur wenigen L\u00e4ndern der Welt wird die perkutane Angioplastie der Koronararterien (PTCA) so h\u00e4ufig eingesetzt wie in Deutschland. Trotz sinkender Pr\u00e4valenz von instabiler Angina pectoris und Myokardinfarkt steigt die Zahl der Katheterinterventionen steil an. Die Indikation zur PTCA wird also kontinuierlich ausgeweitet. Dabei ist ein im Vergleich zur medikament\u00f6sen Therapie g\u00fcnstigerer Effekt der PTCA [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[235,4198,109,110,111,238,2896,2895,112,527,528,87,88,113],"class_list":["post-40196","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-atorvastatin","tag-avert-studie","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-koronarangiografie","tag-koronarangiographie","tag-lipidsenker","tag-pci","tag-perkutane-koronarintervention","tag-perkutane-transluminale-koronare-angioplastie","tag-ptca","tag-statine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie) - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie) - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"In nur wenigen L\u00e4ndern der Welt wird die perkutane Angioplastie der Koronararterien (PTCA) so h\u00e4ufig eingesetzt wie in Deutschland. Trotz sinkender Pr\u00e4valenz von instabiler Angina pectoris und Myokardinfarkt steigt die Zahl der Katheterinterventionen steil an. Die Indikation zur PTCA wird also kontinuierlich ausgeweitet. Dabei ist ein im Vergleich zur medikament\u00f6sen Therapie g\u00fcnstigerer Effekt der PTCA [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"1999-09-01T10:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/09\/Abbildung-1999-69-1.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie)\",\"datePublished\":\"1999-09-01T10:05:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/\"},\"wordCount\":521,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/09\\\/Abbildung-1999-69-1.gif\",\"keywords\":[\"Atorvastatin\",\"AVERT-Studie\",\"Cholesterinsynthese-Hemmer\",\"CSE-Hemmer\",\"HMG-CoA-Reduktase-Hemmer\",\"Hypercholesterin\u00e4mie\",\"Koronarangiografie\",\"Koronarangiographie\",\"Lipidsenker\",\"PCI\",\"Perkutane Koronarintervention\",\"Perkutane transluminale koronare Angioplastie\",\"PTCA\",\"Statine\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/\",\"name\":\"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie) - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/09\\\/Abbildung-1999-69-1.gif\",\"datePublished\":\"1999-09-01T10:05:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/09\\\/Abbildung-1999-69-1.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/1999\\\/09\\\/Abbildung-1999-69-1.gif\",\"width\":500,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie) - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie) - Der Arzneimittelbrief","og_description":"In nur wenigen L\u00e4ndern der Welt wird die perkutane Angioplastie der Koronararterien (PTCA) so h\u00e4ufig eingesetzt wie in Deutschland. Trotz sinkender Pr\u00e4valenz von instabiler Angina pectoris und Myokardinfarkt steigt die Zahl der Katheterinterventionen steil an. Die Indikation zur PTCA wird also kontinuierlich ausgeweitet. Dabei ist ein im Vergleich zur medikament\u00f6sen Therapie g\u00fcnstigerer Effekt der PTCA [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"1999-09-01T10:05:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/09\/Abbildung-1999-69-1.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie)","datePublished":"1999-09-01T10:05:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/"},"wordCount":521,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/09\/Abbildung-1999-69-1.gif","keywords":["Atorvastatin","AVERT-Studie","Cholesterinsynthese-Hemmer","CSE-Hemmer","HMG-CoA-Reduktase-Hemmer","Hypercholesterin\u00e4mie","Koronarangiografie","Koronarangiographie","Lipidsenker","PCI","Perkutane Koronarintervention","Perkutane transluminale koronare Angioplastie","PTCA","Statine"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/","name":"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie) - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/09\/Abbildung-1999-69-1.gif","datePublished":"1999-09-01T10:05:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/09\/Abbildung-1999-69-1.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/1999\/09\/Abbildung-1999-69-1.gif","width":500,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/aggressive-senkung-der-lipide-als-alternative-zur-ptca-avert-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Aggressive Senkung der Lipide als Alternative zur PTCA? (AVERT-Studie)"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40196"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40196\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}